Open AccessThe novel vasopressin receptor (V1aR) antagonist SRX246 reduces anxiety in an experimental model in humans: a randomized proof-of-concept study
Author(s) -
Tiffany R. Lago,
Michael J. Brownstein,
Emily Page,
Emily Beydler,
Adrienne Manbeck,
Alexis Beale,
Camille Roberts,
Nicholas L. Balderston,
Eve Damiano,
Suzanne L. Pineles,
Neal G. Simon,
Monique Ernst,
Christian Grillon
Publication year - 2021
Publication title -
psychopharmacology/psychopharmacologia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.378
H-Index - 196
eISSN - 1432-2072
pISSN - 0033-3158
DOI - 10.1007/s00213-021-05861-4
Subject(s) - startle response , anxiety , vasopressin , psychology , fear potentiated startle , moro reflex , neuropeptide , placebo , antagonist , neuroscience , receptor , pharmacology , medicine , reflex , fear conditioning , psychiatry , alternative medicine , pathology
Arginine vasopressin (AVP) is a neuropeptide that modulates both physiological and emotional responses to threat. Until recently, drugs that target vasopressin receptors (V1a) in the human central nervous system were unavailable. The development of a novel V1a receptor antagonist, SRX246, permits the experimental validation of vasopressin's role in the regulation of anxiety and fear in humans.